Todd Creech

Todd has spent more than ten years as a healthcare CFO, helping build multiple successful companies to profitable exits. In 2016, he joined HealthQuest, bringing his operations and financial experience to innovative companies primed for growth. Todd currently serves on the board or as a board observer of several HealthQuest portfolio companies.

Prior to HealthQuest, he was the Chief Financial Officer and Treasurer of ZS Pharma (IPO in 2014 and sold to AstraZenaca in 2015). Todd was the CFO and led business development activities for Sarcode which developed Xiidra, the first dry-eye pharmaceutical to be approved for both signs and symptoms of dry eye (sold to Shire in 2013; now marketed by Novartis). He was also the CFO of Sirion Therapeutics, an ophthalmic company that successfully developed and received approval for two products (Durezol and Virgan) which was sold to Alcon 2010 after spinning out Virgan to Bausch & Lomb. Between 2015 and 2021 he was also a consulting financial advisor (and acting CFO) to Femasys (NASDAQ:FEMY), a medtech company developing and selling devices targeted at women’s health issues. During his time as CFO, he raised more than $500M in equity and debt, including two IPOs, while helping to build operations and companies that generated more than $3.5B in exits.

Earlier in his career, Todd worked in healthcare venture investing for Quintiles (now IQVIA) and as a consultant at SRI International. He also cofounded two companies: Centice, a spectroscopy platform spinout of Duke University, and TLC Pharma, a specialty pharmaceutical business.

Todd holds bachelor’s degrees in finance and accounting from Miami (Ohio) University, which he attended on a baseball scholarship; and an MBA from Duke University. He is an executive-in-residence for the Moffitt Cancer Center and is a member of theMoffitt board research committee. He is also a member of the Executive Board of the Southeast Life Sciences Association.